SCHEMBL4017822

SCHEMBL4017822

Cc1[nH]c2c(F)ccc(C)c2c1CCNC(=O)/C=C/c1ccccc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.55
HPGD P15428 7/20 0.54
LMNA P02545 6/20 0.54
SMN1; SMN2 Q16637 6/20 0.54
RAB9A P51151 6/20 0.54
NPC1 O15118 5/20 0.54
ALDH1A1 P00352 7/20 0.48
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
ALOX12 P18054 1/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
MAPT P10636 6/20 0.44
TP53 P04637 1/20 0.44
THRB P10828 1/20 0.44
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
PKM P14618 2/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4017528 0.91 MEN1 (0.49) GAAHPGDLMNASMN1; SMN2RAB9A
SCHEMBL4017359 0.91 MEN1 (0.49) GAAHPGDLMNASMN1; SMN2RAB9A
SCHEMBL13982583 0.89 MEN1 (0.48) GAAHPGDLMNASMN1; SMN2RAB9A
SCHEMBL13982460 0.88 MEN1 (0.47) GAAHPGDLMNASMN1; SMN2RAB9A
SCHEMBL4017825 0.87 MMP1 (0.50) HPGDLMNASMN1; SMN2RAB9ANPC1
SCHEMBL4755471 0.87 MEN1 (0.46) GAAHPGDLMNASMN1; SMN2RAB9A
SCHEMBL4017363 0.87 MEN1 (0.62) GAAHPGDLMNASMN1; SMN2RAB9A
SCHEMBL4669261 0.87 ALDH1A1 (0.48) GAAHPGDLMNASMN1; SMN2RAB9A
SCHEMBL4669267 0.87 MEN1 (0.46) GAAHPGDLMNASMN1; SMN2RAB9A
SCHEMBL4017820 0.86 MAPT (0.50) GAALMNASMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2014287-A1 Use of cinnamic acid derivatives as modulators of an EP2 receptor Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP claimed
EP-2014287-A1 Use of cinnamic acid derivatives as modulators of an EP2 receptor Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP disclosed